Maintenance paradigm in non-squamous NSCLC
|
|
- Charleen Webb
- 6 years ago
- Views:
Transcription
1 Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla
2 Agenda Theoretical basis The data The comparisons
3 Agenda Theoretical basis The data The comparisons
4 Pro Continuation Maintenance
5 Pro Continuation Maintenance Why Maintenance Why Continuation
6 Pro Continuation Maintenance Why Maintenance - may have disease under control Why Continuation
7 Maintenance in advanced NSCLC: Treating Before Disease Progression Until Progression or Intolerance Traditional approach 1 st -line treatment platinum doublet chemotherapy (4 6 cycles) Break from treatment 2 nd /3 rd line treatment Diagnosis CR/PR/SD PD PD Maintenance approach Maintenance therapy Increased time to PD Diagnosis CR/PR/SD PD PD
8 Maintenance in Other Chronic Diseases Other Cancers Breast Colorectal Prostate Mesothelioma Respiratory Diseases COPD Granulomatosis Lupus Fibrosis
9 Pro Continuation Maintenance Why Maintenance - may have disease under control Why Continuation - if you are using a different drug, this is not maintenance
10 Maintenance treatment Types Continuation therapy: Prolonged platinum doublet chemotherapy Continuation Maintenance: Continuation of non-platinum agent used in doublet chemotherapy e.g. paclitaxel, gemcitabine, pemetrexed Switch Maintenance: Introduction of a new cytotoxic agent e.g. docetaxel, pemetrexed, erlotinib Stinchcombe, TE et al. J Thoracic Oncol 2009;4:243 50
11 Pro Continuation Maintenance Why Maintenance - may have disease under control Why Continuation - if you are using a different drug, this is not maintenance - we should squeeze the benefit for any single drug
12 Pro Continuation Maintenance Why Maintenance - may have disease under control Why Continuation - if you are using a different drug, this is not maintenance - we should squeeze the benefit for any single drug - continuation maintenance is standard in most oncological contexts (including targeted therapy in lung cancer)
13 Agenda Theoretical basis The data The comparisons
14 Switch Maintenance With Docetaxel Patients without disease progression randomized 1:1 Chemotherapynaive patients with stage IIIB/IV NSCLC (N = 566) Gemcitabine/Carboplatin for 4 cycles Immediate Docetaxel (n = 153) Delayed Docetaxel* (n = 156) *Initiated at first evidence of progressive disease Primary endpoint: OS Other endpoints: PFS, ORR, safety, QOL Fidias PM, et al. J Clin Oncol. 2009;27:
15 Probability of PFS Docetaxel Switch Maintenance: PFS HR=0.71 (95% CI: ) p< Delayed Immediate Mos Patients at Risk, n Delayed Immediate Median PFS delayed vs immediate: 2.7 vs 5.7 mos (P =.0001) 48 Fidias PM, et al. J Clin Oncol. 2009;27:
16 Probability of OS Docetaxel Switch Maintenance: OS Delayed Immediate HR=0.84 (95% CI: ) p< Mos Patients at Risk, n Delayed Immediate Median OS delayed vs immediate: 9.7 vs 12.3 mos (P =.0853) 1-yr survival delayed vs immediate: 43.5% vs 51.1% 60 Fidias PM, et al. J Clin Oncol. 2009;27:
17 JMEN Study Design Double-blind, multicenter, placebo-controlled, phase III trial Randomized 2:1 according to sex, PS, stage, best response, nonplatinum drug, brain metastases Patients with stage IIIB/IV NSCLC, ECOG PS 0-1, 4 prior cycles of gem, doc, or tax + cis or carb, with CR, PR, or SD (N = 663) Pemetrexed 500 mg/m 2 (d1,q21d) + BSC (n = 441)* Placebo (d1, q21d) + BSC (n = 222)* Primary endpoint: PFS *B 12, folate, and dexamethasone given in both arms Cielanu et al., Lancet 2010
18 Probability Maintenance pemetrexed (JMEN): PFS and OS PFS (n=581) OS (n=663) 1.0 Pemetrexed: 4.0 months 1.0 Pemetrexed: 13.4 months Placebo: 2.0 months Placebo: 10.6 months HR=0.599 (95% CI: ) p< HR=0.79 (95% CI: ) p= Time (months) Time (months) Cielanu et al., Lancet 2010
19 Maintenance pemetrexed (JMEN): PFS (n=581) OS (n=663) Cielanu et al., Lancet 2010
20 SATURN: Erlotinib maintenance Erlotinib 150mg/day PD Chemonaïve advanced NSCLC (n=1,949) 4 cycles of 1st-line platinumbased doublet Non-PD (n=889) 1:1 Placebo PD Mandatory tumour sampling Co-primary endpoints PFS in all patients PFS in patients with EGFR IHC+ tumours Secondary endpoints OS in all patients and those with EGFR IHC+ tumours, OS and PFS in EGFR IHC tumours; biomarker analyses; safety; time to symptom progression; quality of life (QoL) Cappuzzo, et al. WCLC 2009
21 PFS probability PFS: Erlotinib versus placebo (ITT) 1.0 Erlotinib (n=437) Placebo (n=447) PFS at 12 weeks (%) PFS at 24 weeks (%) HR=0.71 ( ) Log-rank p< Time (weeks) Cappuzzo, et al. WCLC 2009
22 OS probability OS: Erlotinib versus placebo (ITT) Erlotinib (n=438) Placebo (n=451) HR=0.81 ( ) Log-rank p= Time (months) Cappuzzo, et al. WCLC 2009
23 Advanced NSCLC: Gemcitabine Maintenance Therapy Primary endpoint: PFS Chemotherapy-naive patients with stage IIIB/IV NSCLC and CR / PR / SD after cisplatin + gemcitabine (N = 206) Maintenance gemcitabine 1250 mg/m 2 Days 1, 8 Q3W plus BSC (n = 138) BSC only (n = 68) Brodowicz T, et al. Lung Cancer. 2006;52:
24 Advanced NSCLC: Gemcitabine Maintenance Therapy PFS PFS from the date of starting first-line PFS from the date of randomization HR=0.69 (95% CI: ) p<0.001 OS: 13.0 mos vs 11.0 mos, P =.195 Brodowicz T, et al. Lung Cancer. 2006;52:
25 Gemcitabine Maintenance + BSC vs BSC Alone Patients without disease progression randomized 1:1 Chemotherapynaive patients with stage IIIB/IV NSCLC (N = 519) Gemcitabine/Carboplatin for 4 cycles Gemcitabine + BSC (n = 128) BSC (n = 127) Patients stratified by PS, stage, best tumor response Primary endpoint: OS Other endpoints: PFS, ORR, safety Belani CP, et al. ASCO Abstract 7506.
26 Advanced NSCLC: Gemcitabine Maintenance Therapy PS 2 Belani CP, et al. ASCO Abstract 7506.
27 IFCT-GFPC 0502: Gemcitabine vs Erlotinib vs Observation as Maintenance Patients stratified by sex, histology, smoking status, treatment center, and response/stabilization following first-line therapy Primary endpoint: PFS Other endpoints: OS, safety, symptom control, effect of EGFR status Patients without disease progression randomized 1:1:1 Chemotherapynaive patients with stage IIIB/IV NSCLC Cisplatin/Gemcitabine for 4 cycles Gemcitabine (n = 154) Erlotinib (n = 155) (N = 834) Observation (n = 155) Perol M et al. ASCO 2010: Abstract 7507
28 Gemcitabine or Erlotinib Maintenance PFS Pérol M et al. JCO 2012;30:
29 Gemcitabine or Erlotinib Maintenance Overall survival Pérol M et al. JCO 2012;30:
30 Pemetrexed Maintenance v Placebo in Nonsquamous NSCLC: Phase III Study Patients without disease progression randomized 2:1 Chemotherapynaive patients with stage IIIB/IV nonsquamous NSCLC (N = 900 planned) Pemetrexed/Cisplatin for 4 cycles Pemetrexed + BSC Placebo + BSC Primary endpoint: PFS Other endpoints: OS, ORR, patient-reported outcomes, resource utilization, toxicity Paz-Ares LG, et al. BMC Cancer. 2010;10:85.
31 Survival Probability PARAMOUNT: PFS from Randomization PFS: Primary Efficacy Endpoint PFS: Reassessed at Time of Final OS Survival Probability Pemetrexed Placebo Unadjusted HR: 0.62 ( ) Time (Months) Patients at Risk Pem + BSC Plac+ BSC Patients at Risk Pemetrexed Placebo Unadjusted HR: 0.60 ( ) Time (Months) Pem +BSC Plac + BSC
32 Survival Probability PARAMOUNT: Final OS from Randomization Pemetrexed Placebo Unadjusted HR: 0.78 (95% CI: ); P= Time from Randomization (Months)
33 PARAMOUNT: Post-discontinuation Therapy Pemetrexed (N=359) %* Placebo (N=180) %* Patients Receiving Post Discontinuation Therapy Erlotinib Docetaxel Gemcitabine 10 8 Vinorelbine 8 6 Investigational drug 6 4 Carboplatin 5 4 Paclitaxel 3 3 Pemetrexed 2 4 Cisplatin 1 2
34 Survival probability Survival probability PARAMOUNT: OS Hazard Ratios by subgroups Hazard Ratio CR/PR HR = 0.81 All Randomized Patients (N=539) Stage IV (n=490) Stage IIIB (n=49) Induction Response CR/PR (n=234) Induction Response SD (n=285) Pre-randomization ECOG PS 1 (n=363) Pre-randomization ECOG PS 0 (n=173) Non-smoker (n=117) Smoker )n=418) Male (n=313) Female (n=226) Age < 70 (n=447) Age > 70 (n=92) Age < 65 (n=350) Age > 65 (n=189( Other Histologic Diagnosis (n=32) Large Cell Carcinoma (n=36) Adenocarcinoma (n=471) SD HR = Treatment Hazard Ratio (95%% CI) Time from Randomization (Months) Favors Pemetrexed Favors Placebo
35 PARAMOUNT: Possible Drug-related CTCAEs* Pemetrexed (N=359) Grade 1/2 % Grade 3/4 % Placebo (N=180) Grade 1/2 % Grade 3/4 % Fatigue Nausea Anemia Vomiting Mucositis/stomatitis Neuropathy/sensory Neutropenia Leukopenia ALT (SGPT)
36 PARAMOUNT: Possible Drug-related CTCAEs* Pemetrexed (N=359) Grade 1/2 % Grade 3/4 % Placebo (N=180) Grade 1/2 % Grade 3/4 % Fatigue Nausea Anemia Vomiting Mucositis/stomatitis Neuropathy/sensory Neutropenia Leukopenia ALT (SGPT)
37 AVAPEARL1 Trial Pemetrexed Maintenance v Bevacizumab in Nonsquamous NSCLC: Phase III Study Patients without disease progression randomized 1:1 Chemotherapynaive patients with stage IIIB/IV nonsquamous NSCLC (N = 348) Pemetrexed/Cisplatin/ Bevacizumab for 4 cycles Pemetrexed + Bevacizumab Bevacizumab Primary endpoint: PFS Other endpoints: OS, ORR, QoL, toxicity Available from AVAPERL&rank=1. Accessed 19 March 2012.
38 Progression -free survival from date of randomization(%) AVAPERL: PFS From Randomization a Bev+pem 7.4 months (81 events) Bev 3.7 months (104 events) HR, 0.48 ( ); P <.001 Cont. maintenance bev+pem (n=128) Cont. maintenance bev (n=125) Pts at risk 0 Bev+pem Bev Time (months) a Median follow-up time in ITT population (excluding induction): 8.28 months (bev+pem arm), 7.95 months (bev arm) bev, bevacizumab; cont., continuation; HR, hazard ratio; ITT, intent to treat; pem, pemetrexed; pts, patients. Barlesi et al., ESMO 2011
39 Agenda Theoretical basis The data The comparisons
40 Efficacy: PFS & OS Trial Switch Maintenance N Maintenance drug PFS HR (95% CI) OS HR (95% CI) Westeel et al. 181 Vinorelbine 0.77 ( ) 1.08 ( ) Fidias et al. 309 Docetaxel 0.71 ( ) 0.84 ( ) Capuzzo 889 Erlotinib 0.71 ( ) 0.81 ( ) Ciuleanu et al. 663 Pemetrexed 0.60 ( ) 0.79 ( ) Continuation Maintenance Paz-Ares et al 539 Pemetrexed 0.62 ( ) 0.78 ( ) Brodowicz et al. 206 Gemcitabine 0.69 ( ) 0.84 ( ) Belani et al. 255 Gemcitabine 1.09 ( ) 0.97 ( ) Perol et al. 309 Gemcitabine 0.56 ( ) 0.89 ( )
41 Efficacy: QOL Trial N Maintenance drug QoL & Symptom Control Switch Chemotherapy Maintenance Westeel et al. 181 Vinorelbine NR Fidias et al. 309 Docetaxel No differences Capuzzo 889 Erlotinib Better pain control Cieleanu et al. 663 Pemetrexed Better pain and hemoptisis control Continuation Chemotherapy Maintenance Paz-Ares et al 539 Pemetrexed No detrimental effect Brodowicz et al. 206 Gemcitabine NR Belani et al. 255 Gemcitabine NR Perol et al. 309 Gemcitabine NR
42 PARAMOUNT Induction vs JMDB Median number of induction cycles Response: Response Rate (CR/PR) Disease control rates (CR/PR/SD) PARAMOUNT Induction 4 cycles then pemetrexed maintenance 30.1% 74.5% JMDB 1 st -line treatment with 6 cycles 28.6% 63.8% Toxicity Laboratory toxicities Nonlaboratory toxicities Possibletreatment-related deaths Serious adverse events Supportive care 13.7% 14.8% 1.2% 14.2% almost the same More colony-stimulating factors in PARAMOUNT 21.4% 21.9% 1.0% 16.4% More anti-emetics use in JMDB G Scagliotti et al, abstr 203. WCLC 2011
43 Perol M. Poster presented at ESMO 2010: PD370 Toxicity: Grade III-IV Events
44 Consistent PFS and OS Results in JMEN & Saturn Studies: Greater Benefit in Patients With SD Versus CR/PR SATURN OS JMEN OS ITT population (n=889) CR/PR (n=394) SD (n=487) ITT population (n=663) CR/PR (n=322) SD (n=337) HR Favours Erlotinib Favours placebo HR Favours pemetrexed Favours placebo Cappuzzo F et al Lancet Oncol 11: Belani CP, et al. ASCO 2009 (Abs. CRA8000)
45 Gemcitabine or Erlotinib Maintenance PFS Pérol M et al. JCO 2012;30:
46 Survival probability Survival probability PARAMOUNT: OS Hazard Ratios by subgroups Hazard Ratio CR/PR HR = 0.81 All Randomized Patients (N=539) Stage IV (n=490) Stage IIIB (n=49) Induction Response CR/PR (n=234) Induction Response SD (n=285) Pre-randomization ECOG PS 1 (n=363) Pre-randomization ECOG PS 0 (n=173) Non-smoker (n=117) Smoker )n=418) Male (n=313) Female (n=226) Age < 70 (n=447) Age > 70 (n=92) Age < 65 (n=350) Age > 65 (n=189( Other Histologic Diagnosis (n=32) Large Cell Carcinoma (n=36) Adenocarcinoma (n=471) SD HR = Treatment Hazard Ratio (95%% CI) Time from Randomization (Months) Favors Pemetrexed Favors Placebo
47 Summary Maintenance therapy offers the possibility of continued active treatment to delay disease progression and symptom deterioration Continuation maintenance represents true maintenance. Available data with pemetrexed are relevant and robust (and not inferior to those of switch maintenance), and claim for a change in the treatment paradigm Studies with other compounds and histology are warranted Further studies are ongoing
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationMaintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationin combination with cisplatin as first-line doublet 3 as maintenance agent following non-pemetrexed platinum doublet 4
Overall survival (OS) results from PARAMOUNT study of maintenance plus best supportive care (BSC) versus plus BSC, immediately after induction with - Cisplatin, in patients with advanced Nonsquamous Non-small
More informationMaintenance Treatment for Advanced NSCLC. Yvonne Summers PhD, FRCP ESMO Preceptorship Programme March 2017
Maintenance Treatment for Advanced NSCLC Yvonne Summers PhD, FRCP ESMO Preceptorship Programme March 2017 Milestones in the Palliative Systemic Treatment of NSCLC 1990 2000 2010 2015 Platinum based Chemotherapy
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationMaintenance Treatment of Advanced NSCLC
Maintenance Treatment of Advanced NSCLC Giorgio V. Scagliotti University of Torino Department of Clinical & Biological Sciences giorgio.scagliotti@unito.it UNIVERSTY OF TORINO DEPT. OF OF Maintenance /Consolidation/Sequencing
More informationSao Paulo, Abril 2014
Tratamento de Manutencao e outros Sao Paulo, Abril 2014 Rogerio C. Lilenbaum, M.D. Professor of Medicine Yale Cancer Center Chief Medical Officer Smilow Cancer Hospital What Is Maintenance Therapy? Use
More information1st line chemotherapy and contribution of targeted agents
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy
More informationCytotoxic Maintenance Therapy in Advanced NSCLC: Update State of the Art or State of Confusion
Cytotoxic Maintenance Therapy in Advanced NSCLC: Update State of the Art or State of Confusion Corey J Langer MD, FACP Director Thoracic Oncology Abramson Cancer Center Professor of Medicine Hematology-Oncology
More information11/21/2009. Erlotinib in KRAS Mt patients. Bevacizumab in Squamous patients
Decision-Making in Non-Small Cell Lung Cancer (NSCLC): Moving from Empiric to Personalized & Molecular-based Therapy David R. Gandara, MD University of California Davis Cancer Center Disclosures Research
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationAntiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab
Micro-ambiente tumorale. Antiangiogenici e immunoterapia: miti e realtà Milano, 11 Ottobre 2016 Antiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab Francesco Grossi U.O.S. Tumori
More information1st-line Chemotherapy for Advanced disease
SESSION 3: ADVANCED NSCLC 1st-line Chemotherapy for Advanced disease JY DOUILLARD MD PhD Professor Emeritus in Medical Oncology Chief Medical Officer (CMO) ESMO Lugano CH Percent Survival HISTORICAL BASIS
More informationIs there a role for maintenance therapy in advanced non-small-cell lung cancer?
Review Is there a role for maintenance therapy in advanced non-small-cell lung cancer? Cesare Gridelli*1, Paolo Maione1, Antonio Rossi1, Clorinda Schettino1, Maria Anna Bareschino1, Paola Claudia Sacco1,
More informationEGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS
EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS Federico Cappuzzo Istituto Clinico Humanitas IRCCS Rozzano-Italy The EGFR/HER Family Ligand binding domain
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More information1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC
1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC Dr Ross Soo, FRACP National University Cancer Institute, Singapore National University Health System Cancer Science
More informationASCO Highlights Lung Cancer
ASCO Highlights Lung Cancer Anne S. Tsao, M.D. Director, Mesothelioma Program Assistant Professor July 11, 2009 The University of Texas MD ANDERSON CANCER CENTER Department of Thoracic/Head & Neck Medical
More informationESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME. 1 st line chemotherapy for advanced NSCLC. Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine
ESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME 1 st line chemotherapy for advanced NSCLC Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine 2017 PD-L1 50% Pembrolizuma b [I,A] Courtesy of J.Remon Adapted from
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationSecond-line treatment for advanced NSCLC
UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Life was so simple back in 2008 Di
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationPersonalized maintenance therapy in advanced non-small cell lung cancer
China Lung Cancer Research Highlight Personalized maintenance therapy in advanced non-small cell lung cancer Kazuhiro Asami, Kyoichi Okishio, Tomoya Kawaguchi, Shinji Atagi Department of Clinical Oncology,
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More informationVEGF-Inhibitors in NSCLC. Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany
VEGF-Inhibitors in NSCLC Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Conflicts of interest Advisory Board: AstraZeneca Bristol-Myers Squibb Daiichi Sankyo Eli Lilly Merck
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationStrategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors
Strategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors Miklos Pless Medical Oncology Kantonsspital Winterthur 2 Setting the stage. 1995: Chemotherapy works! Meta-Analysis
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationPlatinum-containing first-line chemotherapy has improved
Original Article PARAMOUNT: Descriptive Subgroup Analyses of Final Overall Survival for the Phase III Study of Maintenance Pemetrexed versus Placebo Following Induction Treatment with Pemetrexed Plus Cisplatin
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Data on first-line Overcoming T790M
More informationMaintenance therapies in advanced non-small-cell lung cancer
Review Maintenance therapies in advanced non-small-cell lung cancer Advanced non-small-cell lung cancer is treated with upfront platinum doublet chemotherapy, which produces moderate survival improvements.
More informationTratamiento de la enfermedad avanzada en cáncer de pulmón
Tratamiento de la enfermedad avanzada en cáncer de pulmón S. Ponce Aix! S. Oncología Médica Hospital Universitario 12 de Octubre Madrid Survival by stage NSCLC Stage Distribution NSCLC Stage 5-year Survival
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationSCIENTIFIC DISCUSSION
European Medicines Agency London, 3 June 2009 Product name: Alimta EMEA/H/C/000564/II/0015 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20)
More informationLUNG CANCER TREATMENT: AN OVERVIEW
LUNG CANCER TREATMENT: AN OVERVIEW KONSTANTINOS N. SYRIGOS, M.D., Ph.D. Αναπλ. Καθηγητής Παθολογίας-Ογκολογίας, Ιατρικής Σχολής Αθηνών. Διευθυντής Ογκολογικής Μονάδας, Νοσ. «Η Σωτηρία». Visiting Professor
More informationNSCLC with squamous histology: Current treatment and new options on horizon
NSCLC with squamous histology: Current treatment and new options on horizon Prof. Yasser A.Kader Professor of Oncology Faculty of Medicine, Cairo University 2015 Lung Cancer: Incidence and Mortality New
More informationCancer Cell Research 14 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of
More informationSecond-line treatment for advanced NSCLC
Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY DISCLOSURE OF INTEREST Speaker Bureau: Eli Lilly, MSD, BI, BMS, Roche, AZ UNIVERSITY
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationBackground. Azzoli CG et al. J Clin Oncol 2009; 2 Sandler A et al. NEJM 2006; 3
A Randomized, Open-Label, Phase III, Superiority Study of Pemetrexed(Pem) + Carboplatin(Cb) + Bevacizumab(Bev) Followed by Maintenance Pem + Bev versus Paclitaxel (Pac)+Cb+Bev Followed by Maintenance Bev
More informationLung cancer is the leading cause of cancer-related death in the
ORIGINAL ARTICLE Bevacizumab Maintenance in Patients with Advanced Non Small-Cell Lung Cancer, Clinical Patterns, and Outcomes in the Eastern Cooperative Oncology Group 4599 Study Results of An Exploratory
More informationAngiogenesis and tumor growth
Anti-angiogenic agents: where we are? Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Angiogenesis and tumor growth Journal of experimental Medicine 1972; 133: 275-88 1 Angiogenesis
More informationMedical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationSponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationMedical Oncology: State of the Art Therapy in Advanced NSCLC: 2011 looking toward 2015
Medical Oncology: State of the Art Therapy in Advanced NSCLC: 2011 looking toward 2015 David R. Gandara, MD University of California Davis Cancer Center Algorithm for Therapy of Advanced Stage NSCLC: 2009
More informationLudger Sellmann 1, Klaus Fenchel 2, Wolfram C. M. Dempke 3,4. Editorial
Editorial Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer the Holy Grail in cancer treatment? Ludger Sellmann 1, Klaus Fenchel
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
More informationLung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
More informationINMUNOTERAPIA I. Dra. Virginia Calvo
INMUNOTERAPIA I Dra. Virginia Calvo LBA62. Health-related quality of life (HRQoL) for Pembrolizumab or placebo plus Carboplatin and Paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC:
More informationDo You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement. Reference Slides Introduction
Do You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement Reference Slides Introduction EML4-ALK Fusion Oncogene Key Driver in 3% to 7% NSCLC Inversion or Translocation
More informationOverview of Lung Cancer :Perspectives from Cancer Genotype. Ji-Youn Han, MD, PhD. Center for Lung Cancer National Cancer Center
Overview of Lung Cancer :Perspectives from Cancer Genotype Ji-Youn Han, MD, PhD. Center for Lung Cancer National Cancer Center Histologic classification of lung cancer Therapeutic plateau reached with
More informationMonoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs
Monoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs Corey J Langer, MD, FACP Director Thoracic Oncology Abramson Cancer Center Professor
More informationHistology: Its Influence on Therapeutic Decision Making
Histology: Its Influence on Therapeutic Decision Making Mark A. Socinski, MD Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology Co-Director, UPMC
More informationErlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy
Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy September 2008 This technology summary is based on information available at the time of research and a
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Pemetrexed (Alimta) for Non-Squamous Non- Small Cell Lung Cancer November 19, 2013
pan-canadian Oncology Drug Review Final Clinical Guidance Report Pemetrexed (Alimta) for Non-Squamous Non- Small Cell Lung Cancer November 19, 2013 DISCLAIMER Not a Substitute for Professional Advice This
More informationExploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
More informationImmunoterapia di 1 linea Evidenze e Prospettive Future
Immunoterapia di 1 linea Evidenze e Prospettive Future Sara Pilotto Oncologia Medica, Dipart. di Medicina, Università di Verona, A.O.U.I. Verona sara.pilotto@univr.it Negrar, 30 ottobre 2018 Disclosures
More informationNew Options for Achieving Individualized Approaches to Non-Small Cell Lung Cancer (NSCLC) Management
New Options for Achieving Individualized Approaches to Non-Small Cell Lung Cancer (NSCLC) Management Ramaswamy Govindan, MD Director Professor of Medicine Director, Thoracic Oncology Program Department
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationCollaborative Practice in the Management of Patients With Cancer. Non-Small Cell Lung Cancer: Management of Patients on Cytotoxic Chemotherapy
Collaborative Practice in the Management of Patients With Cancer Non-Small Cell Lung Cancer: Management of Patients on Cytotoxic Chemotherapy Program Chair Beth Eaby-Sandy, MSN, CRNP, OCN Abramson Cancer
More informationChemotherapy for Advanced Gastric Cancer
Chemotherapy for Advanced Gastric Cancer Andrés Cervantes Professor of Medicine DISCLOSURE OF INTEREST Employment: None Consultant or Advisory Role: Merck Serono, Roche, Beigene, Bayer, Servier, Lilly,
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationCombined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago
Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy
More informationPRACTICE GUIDELINE SERIES
ELLIS et al. PRACTICE GUIDELINE SERIES The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent nonsmall-cell lung cancer: a Canadian
More informationINNOVATION IN LUNG CANCER MANAGEMENT. Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy
INNOVATION IN LUNG CANCER MANAGEMENT Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy FIRST-LINE THERAPY FOR METASTATIC NSCLC IN 216 Stratification for EGFR, ALK
More informationEstado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico
Estado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico Enriqueta Felip Vall d Hebron University Hospital Barcelona, Spain Stage I-II
More informationClinical Activity Lung Cancer. Andrea Camerini Ospedale Versilia
Clinical Activity Lung Cancer Andrea Camerini Ospedale Versilia The three main objectives in advanced NSCLC 1. In advanced/metastatic cancer, palliation is often the primary treatment goal 2. Potential
More informationCurrent Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018
Current Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018 David R. Gandara, MD University of California Davis Comprehensive Cancer Center Disclosures Research Grants: AstraZeneca/Medi,
More informationpan-canadian Oncology Drug Review Initial Clinical Guidance Report Nivolumab (Opdivo) for Non-Small Cell Lung Cancer April 1, 2016
pan-canadian Oncology Drug Review Initial Clinical Guidance Report Nivolumab (Opdivo) for Non-Small Cell Lung Cancer April 1, 2016 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationThe road less travelled: what options are available for patients with advanced squamous cell carcinoma?
Robert Pirker Medical University of Vienna Vienna, Austria The road less travelled: what options are available for patients with advanced squamous cell carcinoma? Disclosures Honoraria for advisory board/consulting
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationCase 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First?
Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Marc Peeters, MD, PhD Head of the Oncology Department Antwerp University Hospital Antwerp, Belgium marc.peeters@uza.be 71-year-old
More informationTreatment of advanced NSCLC in 2013: Algorithm, failures, and perspectives
Treatment of advanced NSCLC in 2013: Algorithm, failures, and perspectives Prof. Christian Manegold Medical Faculty Mannheim University of Heidelberg Disclosures Consultancy: Hoffmann-La Roche, Pfizer,
More informationBiomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard
More informationIs the Neo-adjuvant Approach Better than Adjuvant Approach? Comparative Levels of Evidence: Randomized Trials
Is the Neo-adjuvant Approach Better than Approach? Virginie Westeel University Hospital Besançon, France Perspectives in Lung Cancer Amsterdam, 5-6 March 2010 Comparative Levels of Evidence: Randomized
More informationdoi: /theoncologist originally published online February 3, 2009
Potential Treatment Options After First-Line Chemotherapy for Advanced NSCLC: Maintenance Treatment or Early Second-Line? Cesare Gridelli, Paolo Maione, Antonio Rossi, Marianna Luciana Ferrara, Maria Anna
More informationRecent Therapeutic Advances in Squamous Cell Carcinoma of the Lung
Recent Therapeutic Advances in Squamous Cell Carcinoma of the Lung 2017 Conversations in Oncology in Shanghai, China Prof. Shun Lu Shanghai Lung Cancer Center Shanghai Chest Hospital Affiliated to Medical
More informationImmunotherapeutic Approaches in the Treatment of NSCLC. Keith Kerr, MBChB, FRCPath. Aberdeen Royal Infirmary
01 Immunotherapeutic Approaches in the Treatment of NSCLC Keith Kerr, MBChB, FRCPath. Aberdeen Royal Infirmary Outline 02 Review the concept and evolution of immunotherapy in the treatment of cancer Discuss
More informationOUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER
& OUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER Interim Data Report of TRUST study on patients from Bosnia and Herzegovina
More informationLUNG CANCER. Başak Oyan-Uluç, MD Yeditepe University Hospital Medical Oncology. Best of ASCO, İstanbul
LUNG CANCER Başak Oyan-Uluç, MD Yeditepe University Hospital Medical Oncology Best of ASCO, İstanbul 2012 23.6.2012 Treatment of Metastatic NSCLC EGFR targetted treatments 1st line: EGFR-mutated: Afatinib
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationTreatment of advanced NSCLC in the elderly. Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy)
Treatment of advanced NSCLC in the elderly Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy) Most cancer patients are aged >65 years Ovary Breast NHL Corpus uteri Leukaemias
More informationComparison of Gefitinib versus Docetaxel in Patients with Pre-Treated Non-Small Cell Lung Cancer (NSCLC)
J Lung Cancer 2009;8(2):61-66 Comparison of Gefitinib versus Docetaxel in Patients with Pre-Treated Non-Small Cell Lung Cancer (NSCLC) More effective treatments in first, second, and third-line of metastatic
More informationEdith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes
BEACON: A Phase 3 Open-label, Randomized, Multicenter Study of Etirinotecan Pegol (EP) versus Treatment of Physician s Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously
More informationPemetrexed in the maintenance treatment of advanced non-small cell lung cancer
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SINGLE TECHNOLOGY APPRAISAL (STA) Pemetrexed in the maintenance treatment of advanced non-small cell lung cancer Prepared by Eli Lilly and Company
More information